The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
The study met its primary endpoint with flying colors
The partnership also sets the stage for broader collaboration on rare disease treatments
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
Harbour BioMed brings advanced antibody discovery platforms to the table
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
Subscribe To Our Newsletter & Stay Updated
